Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea Pharmaceutica has submitted a marketing authorization application to Swissmedic for oral alitretinoin in the treatment of severe refractory chronic hand eczema.
Subscribe to our email newsletter
The marketing authorization application seeks approval for oral alitretinoin in the treatment of severe refractory chronic hand eczema (CHE) and is based on a clinical program comprising almost 2000 patients.
Recently, marketing authorization applications for alitretinoin in severe refractory CHE have been submitted to various EU member states.